Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Schizophrenia

  Free Subscription


11.10.2021

1 Acta Psychiatr Scand
3 Biol Psychiatry
1 J Clin Psychiatry
1 J Nerv Ment Dis
1 Neuropsychopharmacology
3 Psychiatry Res
1 Psychol Med
3 Schizophr Res


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Acta Psychiatr Scand

  1. MUSTAFA SS, Malla A, Joober R, Abadi S, et al
    Unfinished business: Functional outcomes in a randomized controlled trial of a three-year extension of early intervention versus regular care following two years of early intervention for psychosis.
    Acta Psychiatr Scand. 2021 Oct 2. doi: 10.1111/acps.13377.
    PubMed         Abstract available


    Biol Psychiatry

  2. HOWES O, Cummings C, Heurich M
    Translation From Genes to Mechanism in Schizophrenia: Are Immune-Synaptic Interactions the Missing Link?
    Biol Psychiatry. 2021;90:593-595.
    PubMed        

  3. PERRY BI, Osimo EF, Khandaker GM
    Risk Prediction in Psychosis: Progress Made and Challenges Ahead.
    Biol Psychiatry. 2021;90:590-592.
    PubMed        

  4. ADAMS RA, Pinotsis D, Tsirlis K, Unruh L, et al
    Computational Modeling of Electroencephalography and Functional Magnetic Resonance Imaging Paradigms Indicates a Consistent Loss of Pyramidal Cell Synaptic Gain in Schizophrenia.
    Biol Psychiatry. 2021 Aug 10. pii: S0006-3223(21)01499.
    PubMed         Abstract available


    J Clin Psychiatry

  5. STEINERT T, Jans F
    Six Cases of Perforated Appendicitis During Clozapine Treatment.
    J Clin Psychiatry. 2021;82.
    PubMed        


    J Nerv Ment Dis

  6. WANG KZ, Dai N, Zai CC, de Bartolomeis A, et al
    Recent Stressful Life Events and Suicidal Ideation in Schizophrenia: A 1-Year Follow-up Study.
    J Nerv Ment Dis. 2021 Oct 5. pii: 00005053-900000000-99058.
    PubMed         Abstract available


    Neuropsychopharmacology

  7. KIM M, Lee TH, Park H, Moon SY, et al
    Thalamocortical dysrhythmia in patients with schizophrenia spectrum disorder and individuals at clinical high risk for psychosis.
    Neuropsychopharmacology. 2021 Oct 4. pii: 10.1038/s41386-021-01180.
    PubMed         Abstract available


    Psychiatry Res

  8. HOMMAN LE, Smart SE, O'Neill F, MacCabe JH, et al
    Attrition in longitudinal studies among patients with schizophrenia and other psychoses; findings from the STRATA collaboration.
    Psychiatry Res. 2021;305:114211.
    PubMed         Abstract available

  9. ZOU DS, Cowan HR, Azis M, Mittal VA, et al
    Reciprocal Social Behavior and Related Social Outcomes in Individuals at Clinical High Risk for Psychosis.
    Psychiatry Res. 2021;306:114224.
    PubMed         Abstract available

  10. MINICHINO A, Singh F, Pineda J, Friederich E, et al
    Corrigendum to 'Biological Motion induced mu suppression is reduced in Early Psychosis (EP) patients with active negative symptoms and Autism Spectrum Disorders (ASD)' [Psychiatry Research 238 (2016) 374-377].
    Psychiatry Res. 2021;306:114177.
    PubMed        


    Psychol Med

  11. LO LLH, Lee EHM, Hui CLM, Chong CSY, et al
    Effect of high-endurance exercise intervention on sleep-dependent procedural memory consolidation in individuals with schizophrenia: a randomized controlled trial.
    Psychol Med. 2021 Oct 7:1-13. doi: 10.1017/S0033291721003196.
    PubMed         Abstract available


    Schizophr Res

  12. PUTHOTA J, Alatorre A, Walsh S, Clemente JC, et al
    Prenatal ambient temperature and risk for schizophrenia.
    Schizophr Res. 2021 Oct 4. pii: S0920-9964(21)00390.
    PubMed         Abstract available

  13. FELDMAN J, Hamlyn A, Rice T
    Social media in screening and monitoring for early intervention in psychosis.
    Schizophr Res. 2021;238:70-72.
    PubMed        

  14. GOLAY P, Ramain J, Jenni R, Klauser P, et al
    Six months functional response to early psychosis intervention program best predicts outcome after three years.
    Schizophr Res. 2021;238:62-69.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Schizophrenia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: